Stock Ratings / Health Care / PIII / forecast

DCGO (43) BMGL (58) EUDA (39) ALPS (57) ⌘ Pro Terminal →

P3 Health Partners Inc. (Class A) (PIII) 12-Month Stock Forecast & Price Target Cone

$4.20 +4.22% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

P3 Health Partners Inc. (Class A) (PIII) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $30.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PIII)Realized 20D OHLCV Swing Band: ±12.5%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PIII Position Size: $10,000

Shares at $4.20: 2381.0 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $2.98

$7,095

$-2,905 (-29.0%)

12M Consensus BaseTarget $3.82

$9,095

$-905 (-9.0%)

12M Bull Case BreakoutTarget $17.73

$42,214

+$32,214 (+322.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$4	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$17	69%	B
JP MorganUS Large-Cap Research	SELL	$3	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PIII)

✓Walkthrough of PIII's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PIII // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +51.62%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.20H $4.36L $3.84C $4.20VOL 19.7K

RES: $10.26SUP: $3.47SMA50: $6.74SMA200: $6.55

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PIII Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PIII Butterfly Map → + Track PIII →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -2.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PIII today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PIII. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PIII today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PIII)

Health Care Rank #726 of 1016 ⚔️ DCGO vs PIII Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PIII vs. DCGO, BMGL, EUDA, ALPS)

Industry: Medical/Nursing Services (29 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, P3 Health Partners Inc. (Class A) (PIII) ranks #726 by composite RQD confidence (38/100, grade D-) and #802 by equity capitalization ($30.5M). Within this direct 5-issuer industry benchmark cohort, PIII leads on earnings valuation at N/A trailing P/E, while PIII leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BMGL currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with PIII at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PIII ACTIVE P3 Health Partners Inc. (Class A)	D-	38/100	—	—	-35.0%	+4.22%	$30.5M	Benchmark Subject
DCGO DocGo Inc.	D-	43/100	—	—	-35.0%	-2.43%	$27.0M	/dcgo-vs-piii →
BMGL Basel Medical Group Ltd	D+	58/100	—	—	—	+3.26%	$36.0M	/bmgl-vs-piii →
EUDA EUDA Health Holdings Limited	D-	39/100	—	43.9%	-35.0%	+1.31%	$46.4M	/euda-vs-piii →
ALPS ALPS Group Inc Ordinary Share	D+	57/100	—	—	—	-0.03%	$54.1M	/alps-vs-piii →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001832511

In its most recent audited fiscal period (FY2025, filed 2025-12-31), P3 Health Partners Inc. (Class A) (PIII) reported GAAP revenue of $1.46B (-2.8% vs. FY2024 revenue of $1.50B , and +15.2% cumulative change since FY2023) , GAAP net income of -$147.9M, operating cash flow of -$91.2M, and free cash flow of -$91.2M (+17.2% YoY). On the balance sheet, PIII closed FY2025 with $656.6M in total assets against $228.4M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.46B	-$147.9M	-$91.2M	-$91.2M	$656.6M	$228.4M
FY2024 (FY)	2024-12-31	$1.50B	-$135.8M	-$110.1M	-$110.1M	$783.4M	$108.9M
FY2023 (FY)	2023-12-31	$1.27B	-$57.8M	-$76.0M	-$76.0M	—	—

3. PIII Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PIII stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, P3 Health Partners Inc. (Class A) (NASDAQ: PIII) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $4.20 (+4.22% 1D, market cap $30.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PIII ranks #726 in composite RQD confidence.

How does PIII compare to DCGO and BMGL in the Health Care sector?

Within the Health Care sector (Medical/Nursing Services), PIII carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DCGO (DocGo Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $27.0M) and BMGL (Basel Medical Group Ltd) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $36.0M). Among the 5-stock peer group, PIII leads on earnings multiple (N/A) while PIII leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PIII?

Per PIII's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001832511), P3 Health Partners Inc. (Class A) generated $1.46B in revenue (-2.8% YoY), -$147.9M in net income, and -$91.2M in free cash flow against $656.6M in total assets and $228.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PIII trading relative to its 50-day, 200-day, and 52-week technical levels?

PIII last traded at $4.20 (+4.22% on volume of 49,912 shares), positioning the stock -37.69% below its 50-day simple moving average ($6.74) and -35.88% below its 200-day simple moving average ($6.55). Across its 52-week range of $1.52 to $16.89, PIII sits at the 17.4% percentile with a 14-day RSI of 32.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.67 to $4.73).

PIII Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is PIII's 12-month stock price target?

P3 Health Partners Inc. (Class A) (PIII) carries a 12-month consensus base price target of $3.82 (-9% from $4.20), with a bull-case target of $17.73 and a bear-case floor of $2.98.

Is PIII stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates PIII D- (Sell — SELL) with an RQD Confidence score of 38/100.

Direct Sub-Reports: PIII RQD Cockpit PIII 12M Forecast PIII Earnings & Move PIII Dividends & DRIP PIII Insiders & 13F PIII Whale Options PIII Profit Sankey PIII News & Why